

# Genome Scan of Schizophrenia

Douglas F. Levinson, M.D., Melanie M. Mahtani, Ph.D., Derek J. Nancarrow, B.Sc.,  
Donna M. Brown, M.S., Leonid Kruglyak, Ph.D., Andrew Kirby, B.A.,  
Nicholas K. Hayward, Ph.D., Raymond R. Crowe, M.D., Nancy C. Andreasen, M.D., Ph.D.,  
Donald W. Black, M.D., Jeremy M. Silverman, Ph.D., Jean Endicott, Ph.D.,  
Lawrence Sharpe, M.D., Richard C. Mohs, Ph.D., Larry J. Siever, M.D., Marilyn K. Walters, M.Sc.,  
David P. Lennon, M.A.P.S., Helen L. Jones, B.Nurs., Deborah A. Nertney, B.Sc.,  
Mark J. Daly, B.S., Madeline Gladis, Ph.D., and Bryan J. Mowry, F.R.A.N.Z.C.P.

---

**Objective:** The goal of this study was to identify chromosomal regions likely to contain schizophrenia susceptibility genes. **Method:** A genomewide map of 310 microsatellite DNA markers with average spacing of 11 centimorgans was genotyped in 269 individuals—126 of them with schizophrenia-related psychoses—from 43 pedigrees. Nonparametric linkage analysis was used to assess the pattern of allele sharing at each marker locus relative to the presence of disease. **Results:** Nonparametric linkage scores did not reach a genomewide level of statistical significance for any marker. There were five chromosomal regions in which empirically derived *p* values reached nominal levels of significance at eight marker locations. There were *p* values less than 0.01 at chromosomes 2q (with the peak value in this region at D2S410) and 10q (D10S1239), and there were *p* values less than 0.05 at chromosomes 4q (D4S2623), 9q (D9S257), and 11q (D11S2002). **Conclusions:** The results do not support the hypothesis that a single gene causes a large increase in the risk of schizophrenia. The sample (like most others being studied for psychiatric disorders) has limited power to detect genes of small effect or those that are determinants of risk in a small proportion of families. All of the most positive results could be due to chance, or some could reflect weak linkage (genes of small effect). Multicenter studies may be useful in the effort to identify chromosomal regions most likely to contain schizophrenia susceptibility genes.

(Am J Psychiatry 1998; 155:741–750)

---

---

Received Aug. 12, 1997; revision received Jan. 6, 1998; accepted Feb. 9, 1998. From the Department of Psychiatry, Allegheny University of the Health Sciences, Philadelphia; the Whitehead Institute for Biomedical Research, Cambridge, Mass.; the Queensland Institute of Medical Research, Brisbane, Australia; the Department of Psychiatry, University of Queensland, and Queensland Centre for Schizophrenia Research, Wolston Park Hospital, Brisbane; Research Genetics, Inc., Huntsville, Ala.; the Mental Health Clinical Research Center and Department of Psychiatry, University of Iowa College of Medicine, Iowa City; the Department of Psychiatry, Mt. Sinai School of Medicine, New York; and the New York State Psychiatric Institute, Columbia University, New York. Address reprint requests to Dr. Levinson, Allegheny University Hospitals-EPPI, 3200 Henry Ave., Rm. 206, Philadelphia, PA 19129.

Supported by NIMH grants MH-45097 and KO2-01207 (Philadelphia), MH-43271, MH-31593, MH-00625, and MH-00735 (Iowa), and MH-42827, MH-48858, MH-45212, and DK-31775 (Mt. Sinai); National Institute on Alcohol and Alcoholism grant AA-08402 (Iowa); VA grant VA-4125-019 (Mt. Sinai); National Health and Medical Research Council (NHMRC) of Australia grants 910234 and 941087, the Rebecca L. Cooper Medical Research Foundation, the Queensland Department of Health, and the NHMRC Network for Brain Research into Mental Disorders (Australia); the Scottish Rite Foundation for Schizophrenia Research, the Allegheny-Singer Research Institute, and the Beukenkamp Foundation (Philadelphia); a Centennial Fellowship from the Medical Research Council of Canada (Dr. Mahtani); and National Center for Human Genome Research Special Emphasis Research Career Award HG-00017 (Dr. Kruglyak).

---

The authors thank Dr. Eric Lander for his advice and support, the staff of the Genome Center at Research Genetics, Inc., Dr. John McGrath, Dr. Harvey Whiteford, Dr. Wilma Bias, Ms. Khanh Huynh, Dr. Catherine Stolle, Dr. Wade Berrettini, Dr. Elizabeth Heiss, Nancy McGrady, Althea Ruffin, Ursula Bosch, Annie Xia, Amy Leung, and Dr. Lodewijk Sandkuijl.

---

**F**amily, twin, and adoption studies suggest that 65%–85% of the susceptibility to schizophrenia can be attributed to genes (1, 2). Thus, when genetic linkage methods using DNA markers became feasible in the 1980s, numerous investigators initiated linkage studies of schizophrenia.

In linkage studies, families with ill members are tested by genotyping the variable sequences (alleles) at DNA marker loci, which are unrelated to the disease. Each person has two alleles for each marker (one of maternal and one of paternal origin). If a disease gene is close to a marker, then offspring who inherit the disease allele will also tend to inherit a nearby marker allele (linkage), because meiotic recombination is unlikely across a short chromosomal distance. Linkage analysis deter-

mines whether ill relatives have inherited the same marker allele more often than expected by chance. If linkage analysis reveals that a disease gene is likely to be found near specific markers, intensive study of that region can be undertaken to identify the gene, determine its physiological role, and assess implications for treatment.

If the location of a gene can be predicted by pathophysiology or from rare cases with chromosomal defects, linkage studies can focus on these candidate regions. Such studies have not yet been successful for schizophrenia (3). An alternative approach is the genome scan strategy, which requires the genotyping and linkage analysis of a map of evenly spaced markers on all chromosomes. A genome scan can be expected to locate a single gene that causes most cases of a disease or (with larger samples) genes that independently cause disease in many cases or that greatly increase the risk of disease while interacting with other genes or nongenetic factors (4–6). The probability of detecting a gene can be predicted by the extent to which mutations in the gene increase the relative risk of disease in siblings of affected persons (cases) relative to the general population ( $\lambda_{\text{sibs}}$ ) and by the frequency of the mutations (7–9). A gene of major effect causing a tenfold or greater increase in risk in all or most cases could be detected in 20–40 families, each with two or three ill members (10). Such a gene would produce a simple dominant or recessive pattern of inheritance. For schizophrenia, total  $\lambda_{\text{sibs}}$  is about 10 (2), but it is unlikely that this high relative risk is due to a single gene. The pattern of inheritance in families suggests that several genes interact to increase risk and that no one gene causes more than a two- to threefold increase (9), suggesting non-Mendelian or complex inheritance. The sample size required to detect linkage increases as  $\lambda_{\text{sibs}}$  drops (particularly below 2) (7, 11) or when a mutation is infrequent.

Like most current genome scans for schizophrenia, the present study was initiated almost 10 years ago and was based on the hypothesis that a gene or genes of major effect might be found in families with multiple cases of illness, even if more complex gene interactions were more generally typical of schizophrenia. Genome scans were considered the best way to test this hypothesis, with the hope that the discovery of such genes could elucidate pathophysiological mechanisms relevant to schizophrenia in general. These studies have been delayed by the difficulty of identifying and recruiting such families and the need to adapt to multiple changes in laboratory and statistical methods. In the meantime, several developments have cast doubt on the major gene hypothesis. No significant, replicable linkage finding has yet emerged (3); and increased understanding of complex inheritance has led to an appreciation of the frequency of false positive results and of the large sample size required to detect genes of small effect (11, 12).

Two previously published schizophrenia genome scans were completed in relatively small samples. Coon et al. (13) studied mostly biallelic markers in nine Utah pedigrees with 35 affected individuals. Moises et al.

(14) studied microsatellite markers in five Icelandic pedigrees with 37 affected individuals and further investigated the 10 most positive markers in 65 pedigrees from multiple centers. Neither study yielded significant evidence for linkage. The present study is the largest schizophrenia genome scan published to date; others of similar or larger size are at or near completion. These emerging data serve as tests of the major gene hypothesis, whose full evaluation requires multiple rigorously conducted genome scans that use diverse samples, diagnostic approaches, and analytic methods. The results reported here are not significant. Given that this is the third genome scan that has failed to produce significant evidence for linkage, the field must squarely face the challenge of studying schizophrenia as a genetically complex disease (15). We discuss below several issues concerning the interpretation of data from single and multiple studies, and whether these data can be used to locate schizophrenia susceptibility genes.

## METHOD

The 43 pedigrees (figure 1) were ascertained in Australia (N=18), Philadelphia (N=14), Iowa (N=8), and New York (N=3); their ethnic backgrounds were European-Caucasian (N=31), African American (N=9), Caribbean-Hispanic (N=1), aboriginal/Micronesian (N=1), and Asian (N=1). Families suspected of having two cases of schizophrenia-related disorders were recruited from clinical and research settings and were included if there was a proband with chronic schizophrenia and either 1) at least two available first- or second-degree relatives with any related disorder or 2) a sibling with schizophrenia. Pedigrees were excluded if a bilineal family history of schizophrenia-related disorder in a relative within two degrees of the proband was demonstrated or suspected. Protocols were approved by human subjects committees, and written informed consent was obtained from all subjects. Modified Schedule for Affective Disorders and Schizophrenia (16) or Comprehensive Assessment of Symptoms and History (17) diagnostic interviews (closely related instruments) were completed with probands and available relatives, and all relevant medical records were obtained for affected individuals. (Data from semistructured interviews for schizotypal and paranoid personality disorders, completed for nonpsychotic subjects, are not included in this analysis.) All available information was reviewed, and a lifetime DSM-III-R diagnosis was made by consensus of two senior diagnosticians at each site, followed by independent cross-site review (by L.S., J.E., D.F.L., and B.J.M.) and discussion of disagreements. Substantial efforts were made to ensure diagnostic consistency through these reviews. For Philadelphia/Australia, pairs of interviewers agreed on psychotic and mood disorder diagnoses in 26 of 27 cases (96%) with an interrater reliability (kappa) of 0.89 for mood and psychosis symptom items. For Iowa, interrater agreement was 93% and kappa was 0.86 for the category of schizophrenia spectrum diagnosis (primarily schizophrenia and schizoaffective disorders). For New York, kappa for axis I disorders was 0.86. The cross-site procedure excluded 12.3% of reviewed cases from the genome scan analysis, mostly because of inadequate documentation.


DNA specimens were available for 126 affected persons, including those with schizophrenia (N=103) and those with other psychoses that co-occur with schizophrenia in families (18–20): chronic schizoaffective disorder (N=4), atypical (nonaffective) psychosis (N=16), delusional disorder (N=2), and schizophreniform disorder (with paranoid personality disorder) (N=1). To prevent inclusion of psychotic mood disorders, which can be misdiagnosed as schizoaffective disorder, we supplemented DSM-III-R criteria with definitions of “classical” mood features (severe melancholic or euphoric mood and associated mood symptoms) and excluded cases with these features. Nine cases of schizo-

typical or paranoid personality disorders were excluded because, while these disorders co-aggregate with schizophrenia, the relative risk is lower than for psychoses (21). To encourage discussion of diagnostic differences across studies, we note from our experience in collaborations that our diagnoses of schizophrenia and schizoaffective disorder are relatively conservative (i.e., in other studies, some of our atypical psychosis cases might be considered to be schizophrenia, and additional schizoaffective cases might be included), but our "other nonaffective psychosis" category is broader than the diagnosis of definite or probable schizophrenia in other studies.

### Genotyping

Genotyping was performed at Research Genetics, Inc., Huntsville, Ala., in 269 subjects, including affected persons, available parents and grandparents, and unaffected siblings when one or both parents were not available. From the 393-marker CHLC/Weber 6.0 map (Web site, <http://genetics.mfddclin.edu/scrset/scrset.6>), a map of 312 fluoresceinated autosomal and X-chromosome microsatellite markers was selected (by M.M.M. and A.K.) on the basis of a preliminary assessment of marker quality. Of these, 310 repeat sequences (241 tetranucleotide, 39 trinucleotide, and 30 dinucleotide) were included in the analyses (figure 2), and two were excluded (see below). Marker names and locations are available by anonymous file transfer protocol: <ftp.auhs.edu>, (subdirectory)/docs/schiz, (file name)schizgen.dat. Total map length was 3,410 centimorgans (cM), with a mean intermarker spacing of 11 cM and a mean marker heterozygosity of 76%. Polymerase chain reactions (30 cycles) for each primer pair and subject were pooled and diluted according to a multiplexing scheme based on allele size range and dye type. Samples were denatured at 95°C for 5 minutes and loaded onto 12-cM-long 4% polyacrylamide/7 M urea 12-cm gels and run at 750 V for 1 hour and 10 minutes on a PE/ABI 377 sequencer. Dinucleotide repeats were run on 36-cm gels at 3000 V for 2 hours for higher resolution. Genotype data, generated by GENESCAN/GENOTYPER software (PE/ABI, Norwalk, Conn.), were reviewed and corrected by two independent readers and discarded in cases of disagreement, unscorable data, or peak heights below 20% maximum height for a given marker. A marker was included if 90% of subjects had scorable genotypes after Mendelian inheritance checking (PEDMANAGER, M.P. Reeve-Daly, unpublished). When Mendelian errors were detected, the marker was rerun for all members of the relevant pedigree, or for all pedigrees if five or more errors were observed for a single marker. Markers that persistently displayed high frequencies of non-Mendelian segregation, inconsistent amplification, or high recombination rates (according to GENEHUNTER's recombinant scoring method [22]) were discarded. For an estimate of reliability, markers tested independently (by M.M.M. and A.K.) with use of the same protocol were concordant in over 99% of subjects.

FIGURE 1. Structures of Pedigrees in a Genome Scan of Schizophrenia<sup>a</sup>




<sup>a</sup>The 43 pedigrees used in the genome scan are shown. Genotyped individuals (N=269) are indicated by small open diamonds to the right. Fully shaded symbols represent individuals with diagnoses of DSM-III-R schizophrenia, schizoaffective psychosis, or other nonaffective psychoses who were considered affected in the linkage analysis. There were 126 such cases in which DNA was available. Unshaded symbols indicate "diagnosis unknown" (i.e., some persons were assessed and found to have no disorder, others were not assessed, while others had diagnoses not considered "affected" under the model used here). Slanted lines surrounding a circle or square indicate a deceased individual. The number of affected individuals per pedigree was two in 12 pedigrees, three in 22 pedigrees, and four in nine pedigrees.

### Statistical Analysis

Nonparametric linkage analysis was performed with GENEHUNTER 1.1 (23). This is a model-free test of the exact probability of observed identical-by-descent marker allele sharing among affected individuals in each pedigree. It was chosen from available model-free methods (24) because it can analyze small pedigrees with diverse structures. To maximize informativeness, multipoint analyses were performed for all markers on each chromosome simultaneously to determine the most likely locations of recombination events. The program also reports the proportion of potential linkage information captured, given the observed marker genotypes. The nonparametric linkage score ( $Z_{all}$ ) is calculated as the sum of Z scores for each pedigree divided by the square root of the number of pedigrees. Simulation studies of our sample demonstrated high correlations (0.66–0.74) between nonparametric linkage scores and lod scores calculated under dominant, recessive, and intermediate models of schizophrenia inheritance (25).


When parental DNA is not available, linkage statistics are more

FIGURE 2. Results of a Genome Scan of Schizophrenia<sup>a</sup>


easily affected by the estimated allele frequencies for each marker. These estimates were based on those observed in the data set, and were calculated by PEDMANAGER, which counts alleles in founders including genotypes that can be inferred with certainty. Given the existence of small but significant racial differences in allele frequencies (26, 27), we determined whether racial differences affected nonparametric linkage scores here. For the 54 markers on chromosomes 1 and 2, allele frequencies were estimated separately for the nine African American and 34 other pedigrees, nonparametric linkage scores were calculated for each subgroup, and a total  $Z_{all}$  score was computed by multiplying the square root of the number in the subgroup, summing these products for the two subgroups, and dividing the resulting sum by the square root of the total number of pedigrees. These scores were compared to those computed on the basis of allele frequencies estimated from the whole sample. Differences were minimal: the mean difference in  $Z_{all}$  scores was 0.04 and the maximum was 0.15, with differences greater than 0.10 for six markers (11%). Therefore, we report results based on allele frequencies estimated from the entire sample.

Since exact reported nonparametric linkage p values are conservative in the absence of perfect informativeness (23), empirical p values were determined by computing  $Z_{all}$  for each of 5,000 simulated replicates (SIMULATE [28]) of the 43-pedigree sample for one unlinked marker with a mean information content of 0.78. From these data, a  $Z_{all}$  of 1.36 (250 of 5,000 replicates) was selected as the threshold for a p value of <0.05 (95% confidence interval=0.0441–0.0565), a  $Z_{all}$  of 1.90 (50 replicates) for a p value of <0.01 (95% confidence interval=0.0074–0.0131), and a  $Z_{all}$  of 2.59 for a p value of <0.001 (expected roughly once per very dense genome scan [29]) (95% confidence interval=0.0003–0.0024).

Power analyses were originally based on the hypothesis of a major single-gene effect; additional power analyses were performed to consider the alternative hypothesis of polygenic inheritance with lower values of  $\lambda_{sibs}$  (29). When the simulation model assumed a major disease locus with  $\lambda_{sibs}$  of 10 or greater and either a dominant or recessive mode of inheritance, the power of the present sample was 0.91–0.99, with reduced power in the presence of increasing genetic heterogeneity (i.e., if the marker was linked to disease in a decreasing proportion of families) (data not shown). For



<sup>a</sup>Shown for each chromosome are multipoint nonparametric linkage ( $Z_{all}$ ) scores (broad line, left y axis) and information content (narrow line, right y axis) as computed by GENEHUNTER 1.1. The total map length for each chromosome is shown under the x axis, with the p terminal to the left. Empirically derived nominal (pointwise) statistical significance is indicated by the shaded bands: shading indicates nonparametric linkage scores with values greater than 1.36 and with  $p < 0.05$ ; nonparametric linkage scores within the darker (upper) shaded band are greater than 1.90 and with  $p < 0.01$ . A solid circle above a marker name indicates  $p < 0.05$ , and two solid circles indicate  $p < 0.01$  at that marker locus.  $Z_{all}$  scores of 0 indicate levels of sharing equal to that expected by chance, and positive scores represent sharing greater than expected by chance. Information content is a measure of the proportion of potential linkage information (for each pedigree, averaged across pedigrees) estimated by the analysis at each point; i.e., information content is reduced to the extent that transmission of parental alleles cannot be determined with certainty.

dominant and recessive models with realistic population-based disease parameter values and  $\lambda_{sibs}$  values of 2, 3, 4, 5, and 6, nonparametric linkage scores were computed for each of 300 replicates simulated with use of each mode of transmission and  $\lambda_{sibs}$  value, assuming a single marker either 1 cM from the disease locus (very close to the marker) or 5 cM away (the maximum distance from a marker in a 10-cM interval). Simulated marker information content was similar to that in the genome scan (0.76–0.80). If  $f_0$  is the penetrance of the normal genotype,  $f_1$  is the penetrance of disease heterozygotes,  $f_2$  is the penetrance of disease homozygotes,  $q$  is the disease allele frequency, and  $K_p$  is the population disease frequency, then for dominant and recessive models, respectively,  $f_0 = 0.001$  and  $f_0 = 0.003$ ;  $f_2$  ranged from 0.023 to 0.10 and from 0.04 to 0.21;  $f_1 = f_2$  and  $f_1 = f_0$ ;  $q = 0.036$ –0.14 and  $q = 0.157$ –0.25; and  $K_p = 0.0067$ –0.008 and  $K_p = 0.00531$ –0.0081.


To avoid problems associated with multiple testing, no other analysis was performed for this sample with these markers. The only other published results for this sample used different markers to follow up others' findings on chromosomes 3, 6, and 8 (30, 31), 22q (32), and Xp13 (22).

## RESULTS

Nonparametric linkage scores for all markers are displayed in figure 2. Their distribution is shown in figure 3; superimposed is the theoretical normal curve for the mean (0.009) and SD (0.738), to which the observed data fit at  $p = 0.96$  (Kolmogorov-Smirnov test) and with minimal skewness (0.268) and kurtosis (0.022). The standard deviation of  $Z_{all}$  is reduced below the expected value of 1 when markers are not fully informative. Marker names and locations, nonparametric linkage scores, p values, and information content are available from our anonymous ftp site as described above.

An empirical p value less than 0.05 was observed at eight markers (not significantly different from the 15 of 310 such p values expected by chance), and an empirical

FIGURE 3. Distribution of Nonparametric Linkage Scores From a Genome Scan of Schizophrenia<sup>a</sup>



<sup>a</sup>The distribution of nonparametric linkage (NPL) scores ( $Z_{all}$ ) at the 310 marker locations is shown. "Count" is the number of markers with NPL scores in the indicated range. The superimposed curve represents a normal distribution with the mean (0.009) and SD (0.738) observed in the marker data. The data fit the normal distribution, with  $p=0.96$  (Kolmogorov-Smirnov test).

$p$  value less than 0.01 was observed at three of these markers (the expected number). On the five chromosomes containing these eight markers, the peak values for each chromosome (with the chromosomal band shown in parentheses) were:  $p<0.01$  for  $Z_{all}=2.02$  at marker D10S1239 (10q23) and  $Z_{all}=2.01$  at D2S410 (2q12-13); and  $p<0.05$  for  $Z_{all}=1.51$  at D4S2623 (4q22-23),  $Z_{all}=1.54$  at D9S257 (9q22), and  $Z_{all}=1.44$  at D11S2002 (11q21).

For power analyses, figure 4 shows probabilities of exceeding three nonparametric linkage score thresholds: 2.59 (nominal  $p<0.001$ ), 2.05 (i.e., power to detect a larger score than any in the present data), and 1.36 ( $p<0.05$ ). There is good power to detect  $Z_{all}=2.59$  for a marker 1 cM from the disease locus with  $\lambda_{sibs}=3$ ; but for a marker 5 cM from the disease locus, there is high power (85%) to detect  $Z_{all}=2.05$  only when  $\lambda_{sibs}$  values are 5 and above. With  $\lambda_{sibs}$  values between 2 and 3, scores between 1.36 and 2.05 are common, and similar scores would be seen for a locus with a higher  $\lambda_{sibs}$  value in 50% of the families (unpublished data).

## DISCUSSION

Although  $p$  values below the 0.05 level of significance were observed at eight markers in five chromosomal regions, linkage studies require more stringent thresholds. For a single-gene disease, the size of the genome (the number of independent regions tested) must be considered, so that a "nominal"  $p$  value of about 0.0001 is equivalent to a 5% genomewide false positive rate (4, p. 65). For complex disorders, a different threshold must be computed, because there is no certainty that linkage will

be found. Lander and Kruglyak (29) showed that with complete information (i.e., a dense scan using one analysis), nominal  $p<0.00002$  would occur by chance about once per 20 scans (genomewide  $p=0.05$ ), and nominal  $p<0.001$  about once per scan (which these authors suggest as a criterion for "suggestive linkage"). Alternatively, simulation-based thresholds can be determined (4, 29); see Holmans and Craddock (33) for an example. By either approach, the present positive results cannot be considered statistically significant.

Thus, the present results do not support the hypothesis of a major gene effect in these families, consistent with the two previous scans (13, 14). A major gene could exist in certain populations, in a chromosomal region not well covered by our map, or in an undetermined subgroup of families. Alternatively, susceptibility to schizophrenia could be largely due to an interaction of several genes, each with a small effect on disease risk (1, 9). Detection of these genetic effects could require larger samples than currently exist, perhaps 500–1,000 pedigrees (11, 12). Multiple loci that interact to increase disease risk are difficult to detect, since each parent may carry several susceptibility alleles; multiple, distinct combinations of these alleles might contribute to disease in different children and in different pedigrees. Thus, for any one locus, the pattern of allele sharing among ill relatives is variable and complex. Among smaller samples, statistical support for linkage will vary because of random (stochastic) variation in the proportion of families in whom disease is associated with inheritance of a particular parental susceptibility allele (34). In any one sample, chromosomal regions containing these genes are the most likely to produce high scores, but the same regions will produce weakly positive and negative scores in some samples. By chance, scores in the same range may be observed in regions that do and that do not contain disease genes, making true and false positives difficult to distinguish statistically.

In this study, we chose to preserve statistical power by applying a single robust linkage test to one diagnostic model, avoiding the need to adjust  $p$  values for multiple testing (23, 29). Some statisticians advocate the use of multiple tests for diverse genetic and diagnostic models, so that the maximum number of true positive regions will be identified as deserving of further study (35), while others advocate the use of at least one dominant and one recessive inheritance model (36). Every approach has potential strengths and limitations. Nonparametric linkage can be used as a single test in a genome scan because it correlates so highly with tests of diverse models of inheritance (23, 25).

Since methodological problems may complicate interpretation of linkage studies, the failure to detect linkage in a single study does not disprove the major gene hypothesis. No report has yet identified a statistically significant finding after correction for multiple testing (3, 13–15, 37–41). It is possible that current psychiatric diagnostic criteria obscure major gene effects by classifying genetically diverse subjects together, although this is difficult to test. Therefore, the present results,

taken together with other available evidence, fail to support the hypothesis that a major gene effect is present in multiply affected families.

Given the failure of individual studies to yield statistically significant results, investigators are proceeding by genotyping additional markers near each study's most positive findings, often in expanded samples. If significant linkage cannot be detected and replicated, it is feasible to identify known genes in candidate regions that have CNS activity, and to determine whether mutations or allelic variations in these genes distinguish ill from well subjects. But many CNS genes remain unknown, and it is currently too

costly to sequence the DNA in all candidate regions to search for these genes, given that the number of candidate regions will proliferate as more studies are reported.


It is possible that collaborative studies of multiple existing samples can provide the power necessary to narrow the search. The first such efforts have produced results that are suggestive ( $p < 0.001$ ) but not significant in large samples studied on chromosomes 6p, 8p, and 22q as discussed below. Final published data from a larger number of scans may reveal certain regions that are among those with the most positive results in several scans. Pragmatically, this is a reasonable basis for selecting regions for more intensive study, but with the caveat that the number of false positive results will proliferate with the number of scans, so that overlapping positives can occur by chance. Adequate evaluation of these regions would require collaborative efforts in which the same markers and statistical analyses are used in multiple samples selected in an unbiased manner (i.e., without regard to their findings in the region under study) (31).

### Comparisons With Findings From Other Studies

We summarize here the published findings from other studies in the regions that showed the most positive results in the present study, as well as regions in which positive evidence has been reported in a number of other studies. Note that the various lod scores mentioned achieve genomewide significance somewhere between values of 3.3 and slightly over 4.0, and none is significant after correction for multiple testing.

**Chromosome 2q.** Five Icelandic pedigrees had positive findings at marker D2S135 ( $p = 0.000001$  by the weighted pairs correlation test—extreme  $p$  values for nonparametric tests in very small samples are generally

FIGURE 4. Power Analyses From a Genome Scan of Schizophrenia<sup>a</sup>



<sup>a</sup>The proportions of simulated sample replicates ( $N = 300$  replicates for each data point) that exceeded the indicated nonparametric linkage ( $Z_{all}$ ) thresholds are shown. Circles indicate the threshold for an empirical nominal  $p < 0.05$  ( $Z_{all} > 1.36$ ), squares indicate  $Z_{all} > 2.05$ , which is higher than any score observed in the present study, and triangles indicate  $Z_{all} > 2.59$  and  $p < 0.001$  ("suggestive" linkage, expected to occur by chance on average once per dense genome scan).  $\Theta$  = distance of the marker from the disease locus. Genetic models are summarized in the text. Results are shown for dominant models; recessive models yielded very similar results.

interpreted cautiously), 7 cM toward the centromere from our peak, but in their second-phase multicenter study of two 2q markers in 65 pedigrees the results were negative (14). A maximum lod score of 1.71 was reported in 14 American and Austrian pedigrees at D2S44 (32 cM toward the q terminal from our peak) for a broad diagnostic model (42).

**Chromosome 4q.** Our peak is more than 60 cM from other chromosome 4 findings for neuropsychiatric disorders (13, 43, 44).

**Chromosome 9q.** Moises et al. (14) reported  $p = 0.05$  at D9S175 in five Icelandic pedigrees (about 20 cM toward the centromere from our peak) and  $p < 0.01$  in their phase 2 sample. Increased chromosome 9 pericentromeric inversions were reported in schizophrenia (45), but findings in linkage studies were negative (46).

**Chromosome 10q.** There are no published positive findings in this region.

**Chromosome 11q.** In a large pedigree, schizophrenia was associated with a 1;11 balanced translocation (breakpoint between TYR and D11S388, 5 cM toward the centromere from our peak), although the authors suggest that relevant genes are more likely to be on chromosome 1 (47). This region has been of interest because the dopamine  $D_2$  receptor gene is about 14 cM away (toward the centromere). A very positive lod score was observed in one of four large French Canadian pedigrees (48), but negative or inconclusive results were reported in multiple other samples (49–56).

Preliminary results have recently been reported for a number of additional genome scans (37–41, 57, 58), but evaluation must await the full published reports.

Our most positive results did not include several regions for which stronger evidence for schizophrenia linkage has been reported by others. An initial positive result on chromosome 22q (59) was followed by a re-



port of suggestive linkage ( $p=0.001$ ) in a multicenter study (32) that included data from the present sample. These findings are near (but not within) the deletion region for velo-cardio-facial syndrome, which can be associated with schizophrenia (60, 61) or mood cycling (62). On chromosome 6p, a result close to significant linkage was reported in one sample (63) and suggestive linkage in another (64), as well as in a multicenter study (31) that included results from the present sample (30). For chromosome 8p, an initial positive report (65) was followed by reports of suggestive linkage in another sample (66) and in a multicenter analysis that included that latter sample and the present sample (31).

### Strengths and Limitations of the Study

Strengths of the present study include independent cross-site review of diagnoses; a map of highly polymorphic markers, most of them trinucleotide and tetranucleotide repeats (which are less prone to genotyping and scoring error than dinucleotide repeats); and the use of a single, robust, multipoint model-free analysis.

Limitations include small sample size and gaps in the map that reduce power in those regions (including some telomeres, as in all current maps). A possible limitation is the sample's racial and ethnic diversity. Since the prevalence and symptoms of schizophrenia are similar around the world, and no familial subtypes have been found, it has been suggested that the same genes determine susceptibility across racial/ethnic groups (although groups may carry different mutations in these genes) (67). However, genetic mechanisms underlying complex traits can differ across populations (68), and this could be true for schizophrenia. For example, chromosome 6p has produced strikingly positive linkage scores in a large Irish sample (63) but not in most other samples (3, 31). There might be a gene on chromosome 6p in which mutations that increase the risk of schizophrenia are more frequent in the Irish than in other groups. Or, differences in linkage scores could be due to methodology (e.g., diagnoses) or stochastic variation. We do not yet know whether homogeneous populations will produce more consistent results. Population differences in marker allele frequencies also influence linkage scores, but we observed only slight changes when frequencies were calculated separately for African American pedigrees. Effects of allele frequencies are minimized when DNA from most parents is available and multipoint analysis is used, as in the present study.

Other limitations, common to all schizophrenia research, include reliance on purely clinical diagnoses and lack of evidence for inherited subtypes. Our diagnostic model (which included schizophrenia-related psychoses but not schizotypal or paranoid personality disorders) is well supported by family studies, but other models might be more powerful. Certainly, the field of schizophrenia research in general would benefit from an examination of differences in diagnostic decisions across studies.

In conclusion, we completed a genome scan of 43

schizophrenia pedigrees and observed nominally significant results in five regions, but no genomewide statistically significant or suggestive linkage. The initial hypothesis of a major gene effect in these multiply affected families was not supported. We plan to study the regions with our most positive results in an expanded sample and with denser marker maps. As additional genome scan results are published, it may be possible to identify chromosomal regions that produce positive results in multiple studies. We urge more systematic collaborative efforts to combine existing samples for the study of these regions, in order to determine whether strong evidence for linkage can be observed in sufficiently narrow regions to permit the identification of schizophrenia susceptibility genes with the use of current technologies.

### REFERENCES

1. Gottesman II, Shields J: A polygenic theory of schizophrenia. *Proc Natl Acad Sci USA* 1967; 58:199-205
2. Tsuang MT, Gilbertson MW, Faraone SV: The genetics of schizophrenia: current knowledge and future directions. *Schizophr Res* 1991; 4:157-171
3. Portin P, Alanen YO: A critical review of genetic studies of schizophrenia, II: molecular genetic studies. *Acta Psychiatr Scand* 1997; 95:73-80
4. Ott J: *Analysis of Human Genetic Linkage*. Baltimore, Johns Hopkins University Press, 1991
5. Levinson DF: Power to detect linkage with heterogeneity in samples of small nuclear families. *Am J Med Genet* 1993; 48:94-102
6. Chen WJ, Faraone SV, Tsuang MT: Linkage studies of schizophrenia: a simulation study of statistical power. *Genet Epidemiol* 1992; 9:123-139
7. James JW: Frequency in relatives for an all-or-none trait. *Ann Hum Genet* 1971; 35:47-49
8. Risch N: Assessing the role of HLA-linked and unlinked determinants of disease. *Am J Hum Genet* 1987; 40:1-14
9. Risch N: Linkage strategies for genetically complex traits, I: multilocus models. *Am J Hum Genet* 1990; 46:222-228
10. Lander ES, Botstein D: Strategies for studying heterogeneous genetic traits in humans by using a linkage map of restriction fragment length polymorphisms. *Proc Natl Acad Sci USA* 1986; 83: 7353-7357
11. Hauser ER, Boehnke M, Guo SW, Risch N: Affected sib-pair interval mapping and exclusion for complex genetic traits: sampling considerations. *Genet Epidemiol* 1996; 13:117-138
12. Kruglyak L, Lander ES: High-resolution genetic mapping of complex traits. *Am J Hum Genet* 1995; 56:1212-1223
13. Coon H, Jensen S, Holik J, Hoff M, Myles-Worsley M, Reimherr F, Wender P, Waldo M, Freedman R, Leppert M, Byerley W: Genomic scan for genes predisposing to schizophrenia. *Am J Med Genet* 1994; 54:59-71
14. Moises HW, Yang L, Kristbjarnarson H, Wiese C, Byerley W, Macciardi F, Arolt V, Blackwood D, Liu X, Sjogren B, Aschauer HN, Hwu H-G, Jang K, Livesley WJ, Kennedy JL, Zoega T, Ivarsson O, Bui M-T, Yu M-H, Havsteen B, Commenges D, Weissenbach J, Schwinger E, Gottesman II, Pakstis AJ, Wetterberg L, Kidd KK, Helgason T: An international two-stage genome-wide search for schizophrenia susceptibility genes. *Nat Genet* 1995; 11:321-324
15. Moldin SO: The maddening hunt for madness genes. *Nat Genet* 1997; 17:127-129
16. Endicott J, Spitzer RL: A diagnostic interview: the Schedule for Affective Disorders and Schizophrenia. *Arch Gen Psychiatry* 1978; 35:837-844
17. Andreasen NC, Flaum M, Arndt S: The Comprehensive Assessment of Symptoms and History (CASH): an instrument for as-



- sessing diagnosis and psychopathology. *Arch Gen Psychiatry* 1992; 49:615-623
18. Levinson DF, Mowry BJ: Defining the schizophrenia spectrum: issues for genetic linkage studies. *Schizophr Bull* 1991; 17:491-514
19. Kendler KS, McGuire M, Gruenberg AM, Spellman M, O'Hare A, Walsh D: The Roscommon Family Study, II: the risk of non-schizophrenic nonaffective psychoses in relatives. *Arch Gen Psychiatry* 1993; 50:645-652
20. Maier W, Lichtermann D, Minges J, Hallmayer J, Heun R, Benkert O, Levinson DF: Continuity and discontinuity of affective disorders and schizophrenia: results of a controlled family study. *Arch Gen Psychiatry* 1993; 50:871-883
21. Webb C, Levinson DF, Gladis M: Schizotypal and paranoid personality in the relatives of patients with schizophrenia and affective disorders: a review. *Schizophr Res* 1993; 11:81-92
22. Dann J, DeLisi LE, Devoto M, Laval S, Nancarrow DJ, Shields G, Smith A, Loftus J, Peterson P, Vita A, Comazzi M, Invernizzi G, Levinson DF, Wildenauer D, Mowry BJ, Collier D, Powell J, Crowe RR, Andreasen NC, Silverman JM, Mohs RC, Murray RM, Walters MK, Lennon DP, Crow TJ: A linkage study of schizophrenia to markers within Xp11 near the MAOB gene. *Psychiatry Res* 1997; 70:131-143
23. Kruglyak L, Daly MJ, Reeve-Daly MP, Lander ES: Parametric and nonparametric linkage analysis: a unified multipoint approach. *Am J Hum Genet* 1996; 58:1347-1363
24. Mowry BJ, Nancarrow DJ, Levinson DF: The molecular genetics of schizophrenia: an update. *Aust NZ J Psychiatry* 1997; 31: 704-713
25. Levinson DF: Linkage analysis of complex disorders with multiple phenotypic categories: simulation studies and application to bipolar disorder data. *Genet Epidemiol* 1997; 14:653-658
26. Dean M, Stephens JC, Winkler C, Lomb DA, Ramsburg M, Boaze R, Stewart C, Charbonneau L, Goldman D, Albaugh BJ, Goedert JJ, Beasley RP, Hwang LY, Buchbinder S, Weedon M, Johnson PA, Eichelberger M, O'Brien SJ: Polymorphic admixture typing in human ethnic populations. *Am J Hum Genet* 1994; 55:788-808
27. Barbujani G, Magagni A, Minch E, Cavalli-Sforza LL: An apportionment of human DNA diversity. *Proc Natl Acad Sci USA* 1997; 94:4516-4519
28. Ott J, Terwilliger JT: Assessing the evidence for linkage in psychiatric genetics, in *Genetic Research in Psychiatry*. Edited by Mendlewicz J, Hippus H. Berlin, Springer-Verlag, 1992, pp 245-249
29. Lander E, Kruglyak L: Genetic dissection of complex traits: guidelines for interpreting and reporting linkage findings. *Nat Genet* 1995; 11:241-247
30. Mowry BJ, Nancarrow DJ, Lennon DP, Sandkuijl LA, Crowe RR, Silverman JM, Mohs RC, Siever LJ, Endicott J, Sharpe L, Walters MK, Hayward NK, Levinson DF: Schizophrenia susceptibility and chromosome 6p24-22. *Nat Genet* 1995; 11:233-234
31. Schizophrenia Linkage Collaborative Group for Chromosomes 3, 6 and 8: Additional support for schizophrenia linkage on chromosomes 6 and 8: a multicenter study. *Am J Med Genet* 1996; 67:580-594
32. Schizophrenia Collaborative Linkage Group for Chromosome 22: A combined analysis of D22S278 marker alleles in affected sib-pairs: support for a susceptibility locus for schizophrenia at chromosome 22q12. *Am J Med Genet* 1996; 67:40-45
33. Holmans P, Craddock N: Efficient strategies for genome scanning using maximum likelihood affected-sib-pair analysis. *Am J Hum Genet* 1997; 60:657-666
34. Suarez BK, Hampe CL, Van Eerdewegh P: Problems of replicating linkage claims in psychiatry, in *Genetic Approaches to Mental Disorders*. Edited by Gershon ES, Cloninger CR. Washington, DC, American Psychiatric Press, 1994, pp 23-46
35. Diehl SR, MacLean CJ: Response to SE Hodge, M Durner, VJ Vieland, DA Greenberg: Better data analysis through data exploration (letter). *Am J Hum Genet* 1993; 53:776-777
36. Greenberg DA, Hodge SE, Vieland VJ, Spence MA: Affecteds-only linkage methods are not a panacea. *Am J Hum Genet* 1996; 58:892-895
37. Faraone S, NIMH Genetics Initiative-Millennium Schizophrenia Consortium: A genome scan of the European-American schizophrenia pedigrees of the NIMH Genetics Initiative (abstract). *Am J Med Genet* 1997; 74:557
38. Williams NM, Rees MI, Holmans P, Daniels J, Fenton I, Cardano AG, Murphy KC, Jones LA, Asherson P, McGuffin P, Owen MJ: Genome search for schizophrenia susceptibility genes using a two-stage sib-pair approach (abstract). *Am J Med Genet* 1997; 74:559
39. DeLisi LE, Kelly M, Shaw S, Cardon L, Smith AB, Hopkins P, Shields G, Loftus J, Laval S, Crow TJ, Sherrington R: Preliminary results of an international genomic scan for schizophrenia (abstract). *Am J Med Genet* 1997; 74:558
40. Byerley W, Polloi A, Dale P, Hoff M, Rosenthal J, Tiobech J, Reimherr F, Wender P, Myles-Worsley M, Coon H: Genome-wide linkage analysis of a large schizophrenia pedigree ascertained from Palau, Micronesia (abstract). *Am J Med Genet* 1997; 74:559
41. Straub RE, MacLean CJ, O'Neill FA, Walsh D, Kendler KS: Genome scan for schizophrenia genes: a detailed progress report in an Irish cohort (abstract). *Am J Med Genet* 1997; 74:559
42. Aschauer HN, Fischer G, Isenberg KE, Meszaros K, Willinger U, Todd RD, Beran H, Strobl R, Lang M, Fuchs K, Sieghart W, Reich T, Cloninger CR: No proof of linkage between schizophrenia-related disorders including schizophrenia and chromosome 2q21 region. *Eur Arch Psychiatr Clin Neurosci* 1993; 243:193-198
43. Barrientos A, Volpini V, Casademont J, Genis D, Manzanares JM, Ferrer I, Corral J, Cardellach F, Urbano-Marquez A, Estivill X, Nunes V: A nuclear defect in the 4p16 region predisposes to multiple mitochondrial DNA deletions in families with Wolfram syndrome. *J Clin Invest* 1996; 97:1570-1576
44. Blackwood D, He L, Morris SW, McLean A, Whitton C, Thomson M, Walker MT, Woodburn K, Sharp CM, Wright AF, Shibasaki Y, St Clair DM, Porteous DJ, Muir WJ: A locus for bipolar affective disorder on chromosome 4p. *Nat Genet* 1996; 12: 427-430
45. Nanko S, Kunugi H, Sasaki T, Fukuda R, Kawate T, Kazamatsuri H: Pericentric region of chromosome 9 is a possible candidate region for linkage study of schizophrenia. *Biol Psychiatry* 1993; 33:655-658
46. Nanko S, Fukuda R, Hattori M, Sasaki T, Dai XY, Gill M, Kuwata S, Shibata Y, Kazamatsuri H: No evidence of linkage or allelic association of schizophrenia with DNA markers at pericentric region of chromosome 9. *Biol Psychiatry* 1994; 36:589-594
47. Muir WJ, Gosden CM, Brookes AJ, Fantes J, Evans KL, Maguire SM, Stevenson B, Boyle S, Blackwood DH, St Clair DM, Porteous DJ, Weith A: Direct microdissection and microcloning of a translocation breakpoint region, t(1;11)(q42.2;q21), associated with schizophrenia. *Cytogenet Cell Genet* 1995; 70:35-40
48. Maziade M, Raymond V, Cliche D, Fournier JP, Caron C, Garneau Y, Nicole L, Marcotte P, Couture C, Simard C, Boivin R, Rodrigue C, Boutin P, De Braekeleer M, Martinez M, Merette C: Linkage results on 11Q21-22 in Eastern Quebec pedigrees densely affected by schizophrenia. *Am J Med Genet* 1995; 60: 522-528
49. Nanko S, Gill M, Owen M, Takazawa N, Moridaira J, Kazamatsuri H: Linkage study of schizophrenia with markers on chromosome 11 in two Japanese pedigrees. *Jpn J Psychiatry Neurol* 1992; 46:155-159
50. Su Y, Burke J, O'Neill FA, Murphy B, Nie L, Kipps B, Bray J, Shinkwin R, Ni Nuallain M, MacLean CJ, Walsh D, Diehl SR, Kendler KS: Exclusion of linkage between schizophrenia and the D2 dopamine receptor gene region of chromosome 11q in 112 Irish multiplex families. *Arch Gen Psychiatry* 1993; 50:205-211
51. Wang ZW, Black D, Andreasen NC, Crowe RR: A linkage study of chromosome 11q in schizophrenia. *Arch Gen Psychiatry* 1993; 50:212-216
52. Gill M, McGuffin P, Parfitt E, Mant R, Asherson P, Collier D, Vallada H, Powell J, Shaikh S, Taylor C, Sargeant M, Clements A, Nanko S, Takazawa N, Llewellyn D, Williams J, Whatley S, Murray R, Owen M: A linkage study of schizophrenia with DNA

- markers from the long arm of chromosome 11. *Psychol Med* 1993; 23:27-44
53. Hovatta I, Seppala J, Pekkarinen P, Tanskanen A, Lonnqvist J, Peltonen L: Linkage analysis in two schizophrenic families originating from a restricted subpopulation of Finland. *Psychiatr Genet* 1994; 4:143-152
54. Karayiorgou M, Kasch L, Lasseter VK, Hwang J, Elango R, Bernardini DJ, Kimberland M, Babb R, Francomano CA, Wolyniec PS, Lamacz M, Nestadt G, Meyers D, Ott J, Childs B, Antonarakis S, Kazazian HH, Housman DE, Pulver AE: Report from the Maryland Epidemiology Schizophrenia Linkage Study: no evidence for linkage between schizophrenia and a number of candidate and other genomic regions using a complex dominant model. *Am J Med Genet* 1994; 54:345-353
55. Kalsi G, Mankoo BS, Curtis D, Brynjolfsson J, Read T, Sharma T, Murphy P, Petursson H, Gurling HM: Exclusion of linkage of schizophrenia to the gene for the dopamine D2 receptor (DRD2) and chromosome 11q translocation sites. *Psychol Med* 1995; 25: 531-537
56. Mulcrone J, Whatley SA, Marchbanks R, Wildenauer D, Altmark D, Daoud H, Gur E, Ebstein RP, Lerer B: Genetic linkage analysis of schizophrenia using chromosome 11q13-24 markers in Israeli pedigrees. *Am J Med Genet* 1995; 60:103-108
57. Wildenauer DB, Albus M, Schwab SG, Hallmayer J, Hanses C, Eckstein GN, Zill P, Hönig S, Lerer B, Ebstein R, Lichtermann D, Trixler M, Borrmann M, Maier W: Searching for susceptibility genes in schizophrenia by affected sib-pair analysis (Germany) (abstract). *Am J Med Genet* 1997; 74:558-559
58. Mallet J on behalf of the European Science Foundation: Molecular neurobiology of mental illness, a European consortium (abstract). *Am J Med Genet* 1997; 74:557-558
59. Pulver AE, Karayiorgou M, Wolyniec PS, Lasseter VK, Kasch L, Nestadt G, Antonarakis S, Housman D, Kazazian HH, Meyers D, Ott J, Lamacz M, Liang K-Y, Hanfelt J, Ullrich G, DeMarchi N, Ramu E, McHugh PR, Adler L, Thomas M, Carpenter WT, Manschreck T, Gordon CT, Kimberland M, Babb R, Puck J, Childs B: Sequential strategy to identify a susceptibility gene for schizophrenia: report of potential linkage on chromosome 22q12-q13.1, part 1. *Am J Med Genet* 1994; 54:36-43
60. Pulver AE, Nestadt G, Goldberg R, Shprintzen RJ, Lamacz M, Wolyniec PS, Morrow B, Karayiorgou M, Antonarakis SE, Housman D, Kucherlapati R: Psychotic illness in patients diagnosed with velo-cardio-facial syndrome and their relatives. *J Nerv Ment Dis* 1994; 182:476-478
61. Karayiorgou M, Morris MA, Morrow B, Shprintzen RJ, Goldberg R, Borrow J, Gos A, Nestadt G, Wolyniec PS, Lasseter VK, Eisen H, Childs B, Kazazian H, Kucherlapati R, Antonarakis SE, Pulver AE, Housman DE: Schizophrenia susceptibility associated with interstitial deletions of chromosome 22q11. *Proc Natl Acad Sci USA* 1995; 92:7612-7616
62. Papolos DF, Faedda GL, Veit S, Goldberg R, Morrow B, Kucherlapati R, Shprintzen RJ: Bipolar spectrum disorders in patients diagnosed with velo-cardio-facial syndrome: does a hemizygous deletion of chromosome 22q11 result in bipolar affective disorder? *Am J Psychiatry* 1996; 153:1541-1547
63. Straub RE, MacLean CJ, O'Neill FA, Burke J, Murphy B, Duke F, Shinkwin R, Webb BT, Zhang J, Walsh D, Kendler KS: A potential vulnerability locus for schizophrenia on chromosome 6p-24-22 and evidence for genetic heterogeneity. *Nat Genet* 1995; 11:287-293
64. Schwab SG, Albus M, Hallmayer J, Honig S, Borrmann M, Lichtermann D, Ebstein RP, Ackenheil M, Lerer B, Risch N, Maier W, Wildenauer D: Evaluation of a susceptibility gene for schizophrenia on chromosome 6p by multipoint affected sib-pair linkage analysis. *Nat Genet* 1995; 11:325-327
65. Pulver AE, Lasseter VK, Kasch L, Wolyniec P, Nestadt G, Blouin JL, Kimberland M, Babb R, Vourlis S, Chen H, Laliotti M, Morris MA, Karayiorgou M, Ott J, Meyers D, Antonarakis SE, Housman D, Kazazian D: Schizophrenia: a genome scan targets chromosomes 3p and 8p as potential sites of susceptibility genes. *Am J Med Genet* 1995; 60:252-260
66. Kendler KS, MacLean CJ, O'Neill FA, Burke J, Murphy B, Duke F, Shinkwin R, Easter SM, Webb BT, Zhang J, Walsh D, Straub RE: Evidence for a schizophrenia vulnerability locus on chromosome 8p in the Irish Study of High-Density Schizophrenia Families. *Am J Psychiatry* 1996; 153:1534-1540
67. Risch N: Genetic linkage and complex diseases, with special reference to psychiatric disorders. *Genet Epidemiol* 1990; 7:3-16
68. Weiss KM: *Genetic Variation and Human Disease*. Cambridge, England, Cambridge University Press, 1993